Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.21
(2.56%)
CNY 3.21
(2.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion CNY | -6.12% |
| 2022 | 1.26 Billion CNY | -17.4% |
| 2021 | 1.52 Billion CNY | 7.83% |
| 2020 | 1.41 Billion CNY | -25.63% |
| 2019 | 1.9 Billion CNY | 43.48% |
| 2018 | 1.32 Billion CNY | -18.95% |
| 2017 | 1.63 Billion CNY | -13.25% |
| 2016 | 1.88 Billion CNY | 37.07% |
| 2015 | 1.37 Billion CNY | 53.05% |
| 2014 | 899.62 Million CNY | 31.48% |
| 2013 | 684.22 Million CNY | 125.24% |
| 2012 | 303.77 Million CNY | 105.54% |
| 2011 | 147.79 Million CNY | -30.49% |
| 2010 | 212.62 Million CNY | 22.32% |
| 2009 | 173.82 Million CNY | 19.14% |
| 2008 | 145.9 Million CNY | 14.3% |
| 2007 | 127.65 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.05 Billion CNY | -7.28% |
| 2024 Q1 | 1.13 Billion CNY | -3.9% |
| 2024 Q3 | 1.15 Billion CNY | 9.28% |
| 2023 Q3 | 1.23 Billion CNY | -2.5% |
| 2023 Q2 | 1.26 Billion CNY | 4.05% |
| 2023 Q1 | 1.22 Billion CNY | -3.24% |
| 2023 Q4 | 1.18 Billion CNY | -4.36% |
| 2023 FY | 1.18 Billion CNY | -6.12% |
| 2022 FY | 1.26 Billion CNY | -17.4% |
| 2022 Q3 | 1.29 Billion CNY | -7.22% |
| 2022 Q4 | 1.26 Billion CNY | -2.53% |
| 2022 Q1 | 1.41 Billion CNY | -7.46% |
| 2022 Q2 | 1.39 Billion CNY | -1.3% |
| 2021 Q4 | 1.52 Billion CNY | 18.35% |
| 2021 FY | 1.52 Billion CNY | 7.83% |
| 2021 Q1 | 1.42 Billion CNY | 0.49% |
| 2021 Q2 | 1.32 Billion CNY | -6.86% |
| 2021 Q3 | 1.29 Billion CNY | -2.65% |
| 2020 Q4 | 1.41 Billion CNY | -11.67% |
| 2020 Q2 | 1.48 Billion CNY | 7.15% |
| 2020 Q1 | 1.38 Billion CNY | -27.37% |
| 2020 FY | 1.41 Billion CNY | -25.63% |
| 2020 Q3 | 1.6 Billion CNY | 8.2% |
| 2019 Q3 | 1.91 Billion CNY | -4.6% |
| 2019 Q2 | 2.01 Billion CNY | 2.47% |
| 2019 FY | 1.9 Billion CNY | 43.48% |
| 2019 Q4 | 1.9 Billion CNY | -0.81% |
| 2019 Q1 | 1.96 Billion CNY | 47.97% |
| 2018 FY | 1.32 Billion CNY | -18.95% |
| 2018 Q1 | 1.46 Billion CNY | -10.67% |
| 2018 Q2 | 1.34 Billion CNY | -7.74% |
| 2018 Q3 | 1.43 Billion CNY | 6.38% |
| 2018 Q4 | 1.32 Billion CNY | -7.55% |
| 2017 Q1 | 1.94 Billion CNY | 2.92% |
| 2017 Q4 | 1.63 Billion CNY | -3.0% |
| 2017 Q3 | 1.68 Billion CNY | -6.94% |
| 2017 Q2 | 1.81 Billion CNY | -6.62% |
| 2017 FY | 1.63 Billion CNY | -13.25% |
| 2016 Q2 | 1.3 Billion CNY | -15.12% |
| 2016 Q1 | 1.53 Billion CNY | 11.36% |
| 2016 FY | 1.88 Billion CNY | 37.07% |
| 2016 Q4 | 1.88 Billion CNY | 29.92% |
| 2016 Q3 | 1.45 Billion CNY | 11.61% |
| 2015 Q1 | 1.16 Billion CNY | 29.4% |
| 2015 FY | 1.37 Billion CNY | 53.05% |
| 2015 Q4 | 1.37 Billion CNY | 9.6% |
| 2015 Q3 | 1.25 Billion CNY | -7.13% |
| 2015 Q2 | 1.35 Billion CNY | 16.21% |
| 2014 Q1 | 781.06 Million CNY | 14.15% |
| 2014 FY | 899.62 Million CNY | 31.48% |
| 2014 Q4 | 899.62 Million CNY | 15.66% |
| 2014 Q3 | 777.83 Million CNY | -5.91% |
| 2014 Q2 | 826.7 Million CNY | 5.84% |
| 2013 Q4 | 684.22 Million CNY | 56.13% |
| 2013 FY | 684.22 Million CNY | 125.24% |
| 2013 Q2 | 406.81 Million CNY | 30.48% |
| 2013 Q3 | 438.24 Million CNY | 7.73% |
| 2013 Q1 | 311.78 Million CNY | 2.64% |
| 2012 FY | 303.77 Million CNY | 105.54% |
| 2012 Q1 | 155.85 Million CNY | 5.45% |
| 2012 Q2 | 223.75 Million CNY | 43.57% |
| 2012 Q3 | 250.03 Million CNY | 11.74% |
| 2012 Q4 | 303.77 Million CNY | 21.5% |
| 2011 Q2 | 138.6 Million CNY | -34.38% |
| 2011 Q3 | 148.43 Million CNY | 7.09% |
| 2011 FY | 147.79 Million CNY | -30.49% |
| 2011 Q4 | 147.79 Million CNY | -0.43% |
| 2011 Q1 | 211.22 Million CNY | -0.66% |
| 2010 Q2 | 206.34 Million CNY | 0.0% |
| 2010 FY | 212.62 Million CNY | 22.32% |
| 2010 Q4 | 212.62 Million CNY | 0.0% |
| 2009 FY | 173.82 Million CNY | 19.14% |
| 2008 FY | 145.9 Million CNY | 14.3% |
| 2007 FY | 127.65 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 26.67 Billion CNY | 95.561% |
| Realcan Pharmaceutical Group Co., Ltd. | 11.07 Billion CNY | 89.307% |